Clinical supervision: what do we know and what do we need to know? A review and commentary

AIMS: This study is addressed to nurses but the issues are of equal concern to both midwives and health visitors. Clinical supervision ideally both challenges nurses as well as help their practice. There is need to identify critical elements that help professional practice and understand more clearly the changing nature of supervisory relationships. BACKGROUND: Clinical supervision in nursing is over a decade old in the UK and yet emerging nursing literature suggests that many ideas remain unfamiliar to nursing practice. The resistance shown by nurse towards clinical supervising remains perplexing. Moreover, ideas concerning clinical supervision have been applied without a substantive evidence base. METHODS: The discussion draws on varied ideas concerning supervision, including those outside of nursing, to ask what do we know and still need to know about clinical supervision. This study suggests that, a single approach to clinical supervision could be unhelpful to nursing. FINDINGS AND CONCLUSION: Nursing knowledge concerning many aspects of clinical supervision is increasing because of research. Much of the literature suggests that clinical supervision is scholarly activity requiring much the same attention to relationships as the therapeutic activities it supports. This discussion concludes with the idea that clinical supervision might work at its best as a quiet activity allowing nurses to think about nursing work in ways that suit individual learning styles.     

Suicide among Asian Americans: what do we know? What do we need to know?

The current review begins with an acknowledgment of the diversity within the Asian American population as well as the scarcity of information on suicide among this particular racial/ethnic minority group. In analyzing what is known and what still needs to be learned about suicide among Asian Americans, the current article provides a critical review of significant factors such as age, gender, religious and spirituality issues, acculturation, social support, familial dynamics, social integration as well as gay/lesbian/bisexual orientations. In examining these factors, recommendations related to interventions and the existing research gaps are also discussed.     

Use of artemether–lumefantrine to treat malaria during pregnancy: what do we know and need to know?

Artemether–lumefantrine is a fixed-dose combination containing 20 mg artemether/120 mg lumefantrine per tablet, used for treating uncomplicated malaria in patients weighing ≥5 kg. It is the first artemisinin-based combination registered in some European countries and in the USA. It is marketed in Europe as Riamet^® (Novartis, Basel, Switzerland) and in malaria-endemic countries as Coartem^® (Novartis). Safety concerns prevent early pregnancy usage, while limited postmarketing surveillance has delayed safety assessment and policy development. Large clinical studies, postmarketing surveillance and pharmacovigillance ongoing in some countries may soon bridge safety issues. Fatty diet requirements for optimal absorption, pregnancy-induced changes in pharmacokinetics, pregnancy-related anorexia and food taboos, and emerging reduced parasite sensitivity to artemisinin, challenges optimal artemether–lumefantrine dosing and efficacy during pregnancy. This evaluation addresses drug usage, safety concerns following early exposure, implications for changed pharmacokinetics and reduced parasite susceptibility. Clinical-use updates and strategies to address some knowledge gaps including key operational research are discussed.     

Lung-protective ventilation strategies in neonatology: what do we know--what do we need to know?

OBJECTIVE: Randomized controlled trials (RCTs) investigating various lung-protective ventilation modes or strategies in newborn infants have failed to show clear differences in mortality or bronchopulmonary dysplasia. This review tries to identify possible reasons for this observation, applying modern concepts on ventilator-induced lung injury and lung-protective ventilation. DATA SOURCE: Published RCTs and systematic reviews on mechanical ventilation in newborn infants were identified by searching PubMed and the Cochrane Library. DATA SYNTHESIS: A total of 16 RCTs and four systematic reviews comparing high-frequency ventilation with conventional mechanical ventilation (CMV) failed to show consistent differences in mortality and bronchopulmonary dysplasia. Unfortunately, clear information or data on ventilation and oxygenation targets in the search for optimal lung volumes during high-frequency ventilation or CMV is lacking in many RCTs, questioning the validity of the results and the meta-analytic subgroup analysis. Based on improvement in oxygenation, only three RCTs successfully applied the optimal lung volume strategy during high-frequency ventilation. A total of 24 RCTs and three systematic reviews comparing various CMV modes and settings and two RCTs investigating permissive hypercapnia reported no differences in mortality or bronchopulmonary dysplasia. However, the intervention arms in these RCTs did not differ in tidal volume or positive end-expiratory pressures, variables that are considered important determinants in ventilator-induced lung injury. In fact, no RCT in newborn infants has substantiated so far the experimental finding that avoiding large tidal volumes and low positive end-expiratory pressure during CMV is lung protective in newborn infants. CONCLUSION: RCTs investigating lung-protective ventilation in neonates have mainly focused on comparing high-frequency ventilation with CMV. Most of these RCTs show weaknesses in the design, which may explain the inconsistent effect of high-frequency ventilation on bronchopulmonary dysplasia. RCTs on CMV only focused on comparing various modes and settings, leaving the important question whether reducing tidal volume or increasing positive end-expiratory pressure is also lung protective in newborn infants unanswered.     

International haemovigilance: what have we learned and what do we need to do next?

The International Haemovigilance Network (IHN) defines haemovigilance as ‘a set of surveillance procedures covering the whole transfusion chain (from the collection of blood and its components to the follow‐up of recipients), intended to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products, and to prevent their occurrence or recurrence’. IHN, the International Society of Blood Transfusion and World Health Organization work together to support both developing and established haemovigilance systems. Haemovigilance systems provide valuable data on a range of adverse events related to blood donation and clinical transfusion, from donor syncopal events to transfusion‐transmitted infections, immunological complications and the impact of human errors. Harmonised definitions for most adverse reactions have been developed and validated internationally. Definitions of pulmonary complications are again under review. Haemovigilance data have resulted in changes in policy, products and practice, and can complement and inform clinical audit and research, leading to improved blood donor safety, optimised product use and better clinical outcomes after transfusion. However, more work is needed. Not all countries have haemovigilance systems in place. More robust data and careful analysis are required to improve the understanding of the causes, occurrence and clinical outcomes of these events. Wider dissemination of results will facilitate health policy development internationally, and implementation of haemovigilance recommendations will support further important progress in blood safety.     

Domestic violence and alcohol: what is known and what do we need to know to encourage environmental interventions?

This paper reviews evidence regarding alcohol and domestic violence, including cross-sectional and longitudinal surveys, experimental studies of aggression and marital conflict, event-based research, and intervention studies with alcoholics. Based on this review, it is concluded that alcohol is a contributing cause in domestic violence, but neither a necessary nor sufficient cause. In addition, the evidence suggests that intoxication in the perpetrator of violence does not appear to excuse his aggression, but that intoxication in the victim is often viewed as an excuse for the perpetrator's behavior. Based on this review, several tentative policy implications are discussed. In general, policies that reduce drinking, aggressive tendencies and conflict should have beneficial effects. Alcohol intervention/prevention should focus on men in the early stages of aggressive behavior and should include goals of reduced intoxication and management of anger/conflict. For more severe populations, alcohol interventions might have a beneficial impact, but they must be included as additional requirements in the overall criminal justice response, not as an alternative for other requirements. Finally, it is critical that research regarding alcohol and domestic violence move beyond simple studies of association and begin to frame these questions with an eye toward policy implications.     

You know what we need?

I've listened to many of you moan about the current flat NIH budgets, lack of funding, and the frustration of being a scientist in the current depressed economy. Instead of complaining to only ourselves in the scientific community, we need to make ourselves heard by politicians and the public at large. We need a pundit.     

Endosurgery: what do we need?

A paradigm shift in therapeutic endoscopy occurred with the advent of mucosectomy for the treatment of mucosal neoplasms and suture plication for gastroesophageal reflux disease. The objectives changed from finding simple, easy, and quick alternatives to surgery to reproducing surgical results. A radical version of flexible endoscopy has emerged to meet new goals of full-thickness resections, creation of anastomoses, and lumen reconfiguration. This will require a new generation of endosurgical tools that cut, stitch, and staple with added dimensions of multiaxis orientation and triangulation.     

Cytotoxic chemotherapy: what do community nurses need to know?

Among the range of increasingly complex care demands made of community nurses in the UK is the support of patients undergoing cytotoxic chemotherapy at home. The NHS Cancer Plan and associated standards (Department of Health, 2000a,b) have identified that community nurses need an increased awareness and knowledge of the procedures and drugs involved to ensure a quality service provision. This article, based on a validated education course commissioned for community nurses in East Berkshire, explores key areas that enable community staff to care for and support patients through the course of their treatment and allows them to begin identifying an operational structure that promotes a quality service. Health and safety (as part of risk management) routes of administration, recognizing neutropenic sepsis associated with chemotherapy, and communication and collaboration are presented as key points identified from the course.     

Clinical end points in baroreflex activation therapy: what do we need to know?

Many studies have shown that the sympathetic nervous system plays an important part in blood pressure regulation. One of its components is the baroreceptor reflex, which buffers sudden and also potentially chronic changes in blood pressure. The carotid baroreceptors have become a new target in the treatment of hypertensive patients in whom optimal antihypertensive medication fails to normalize the pressure. By electrically stimulating the baroreceptor area, it is now possible to substantially reduce blood pressure in such patients and the effect is well maintained over a prolonged period of time. The hypotensive response is associated with a fall in muscle sympathetic nerve activity, which lends support to the view that baropacing suppresses overall sympathetic outflow from the brain. The procedure appears to be safe and well tolerated. Nevertheless, the authors still need definite proof from prognostic trials that baropacing is superior to intensified medical treatment.     

Fluoroquinolone-induced tendinopathy: what do we know?

Fluoroquinolones are relatively safe, effective antibiotics. As their use becomes more frequent, so will the adverse side effects. I highlight a rare but debilitating adverse reaction-fluoroquinolone-induced tendinopathy. Case reports and letters from 1987 to 1998 were identified by using Grateful Med and PubMed Internet accesses to the National Library of Medicine. Articles were reviewed for clinical practicality. There are few articles on fluoroquinolone-induced tendinopathy in the US literature targeting primary care physicians. This entity has been described in many case reports, but little has been done to isolate the causative agents. Incidence of this side effect is difficult to estimate, since no prospective studies are available for review or calculation of risk. Fluoroquinolone-induced tendinopathy appears more commonly in tendons under high stress. The cause is probably multifactorial. Risk factors for the development of fluoroquinolone-induced tendinopathy are age, renal failure, corticosteroid use, and previous tendinopathy from fluoroquinolones.